BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 18, 2024
Finance

Venture Report: Five biotechs raise nearly $800M in two-day flurry 

Plus: New capital for CytoReason, Truvian and Renalys
BioCentury | Oct 27, 2021
Finance

Bain commits $300M to advance Cardurion’s CV programs

Bain Capital Life Sciences makes first big splash from new $1.9B third fund
BioCentury | Aug 27, 2021
Distillery Therapeutics

CaMKII gene therapy to preserve retinal ganglion cells

BioCentury | Aug 27, 2021
Distillery Therapeutics

Brain metabolite analog to treat ischemic stroke

BioCentury | Aug 27, 2020
Distillery Therapeutics

siRNAs against plaque-destabilizing molecule CAMK2G for atherosclerosis

DISEASE CATEGORY: Cardiovascular
INDICATION: Atherosclerosis Nanoparticles carrying siRNAs against CAMK2G, a plaque-destabilizing molecule expressed by macrophages, could treat atherosclerosis.
BioCentury | Jun 26, 2020
Distillery Therapeutics

FMR1 peptide therapy for Fragile X syndrome

BioCentury | Jun 18, 2019
Distillery Therapeutics

CAMKK2 identified as target for breast cancer

BioCentury | May 15, 2019
Translation in Brief

Lentiviral gene therapy could offer relief to refractory epilepsy patients

An epilepsy gene therapy from UCL could offer an alternative to brain surgery
BioCentury | May 6, 2019
Distillery Therapeutics

KCNA1 gene therapy for epilepsy

Items per page:
1 - 10 of 72